TransMedics Group (NASDAQ:TMDX) Issues Earnings Results

TransMedics Group (NASDAQ:TMDX) announced its earnings results on Tuesday. The company reported $0.44 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.06), FiscalAI reports. The company had revenue of $189.95 million during the quarter, compared to analysts’ expectations of $184.00 million. TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. The company’s revenue for the quarter was up 20.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.92 earnings per share.

Here are the key takeaways from TransMedics Group’s conference call:

• Record second-quarter performance: Revenue reached approximately $190 million, up 21% year over year, while service revenue rose 29% and logistics revenue increased 39%. The company attributed the strength to higher OCS utilization, new centers, logistics market-share gains, pricing adjustments, and improved fleet efficiency.
• TransMedics raised the low end of its 2026 revenue guidance to $737 million-$757 million, representing 22%-25% growth, and ended the quarter with approximately $473 million in cash and equivalents. The guidance excludes meaningful contributions from PAD Aviation, ENHANCE Part B, and DENOVO.
• Management is prioritizing long-term growth investments over near-term profitability, including OCS Kidney, next-generation OCS, clinical programs, international infrastructure, and new facilities. As a result, full-year adjusted operating-margin guidance was reduced to approximately 12.5%-14% from the prior expectation of about 16%.
• The OCS Kidney program is entering engineering and manufacturing verification, with pre-IDE discussions underway and first clinical experience targeted for 2027. ENHANCE Heart Part B and DENOVO Lung remain dependent on FDA review; management said only a handful of cases have been completed so far and expects meaningful contribution later than originally anticipated.
• TransMedics closed its investment in Germany-based PAD Aviation to establish a European transplant-logistics network, with Italy the initial commercial focus and reimbursement expected later in 2026 or early 2027. PAD is expected to be margin-dilutive initially, but provides European aviation licensing, pilots, fleet access, and eligibility for regional logistics tenders.

TransMedics Group Price Performance

Shares of NASDAQ TMDX opened at $80.75 on Wednesday. The firm has a market capitalization of $2.79 billion, a P/E ratio of 18.35 and a beta of 1.90. TransMedics Group has a one year low of $60.10 and a one year high of $156.00. The company’s fifty day moving average is $73.01 and its two-hundred day moving average is $99.72. The company has a debt-to-equity ratio of 1.70, a quick ratio of 6.19 and a current ratio of 6.74.

More TransMedics Group News

Here are the key news stories impacting TransMedics Group this week:

• Positive Sentiment: Revenue and full-year outlook exceeded expectations. Second-quarter revenue rose 20.7% year over year to approximately $189.95 million, ahead of the $184 million consensus estimate. TransMedics also forecast fiscal 2026 revenue of $737 million to $757 million, above the roughly $733.6 million analyst consensus. TransMedics Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Analyst remains constructive despite reducing its target. Needham cut its TransMedics price target from $142 to $106 but maintained a “Buy” rating, implying substantial upside from recent trading levels. The lower target reflects more cautious expectations, but the continued Buy rating may limit the negative impact. Needham Price Target Update
• Neutral Sentiment: Management discussed second-quarter results on its earnings call. Investors are evaluating the company’s growth trajectory, profitability and updated outlook following the quarterly release. TransMedics Q2 2026 Earnings Call Transcript
• Negative Sentiment: Earnings fell short of expectations and declined sharply year over year. TransMedics reported quarterly EPS of $0.44, below the $0.50 consensus estimate and down from $0.92 a year earlier. Profitability also weakened, with reported operating profit and net income declining despite continued revenue growth. TransMedics Earnings Miss Estimates
• Negative Sentiment: Additional overhangs include legal scrutiny and insider selling. Rosen Law Firm announced an investigation into potential fiduciary-duty breaches involving company directors and officers. Separately, reported insider activity over the past six months showed sales but no purchases, which may weigh on investor sentiment. Rosen Law Firm Investigation

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on TMDX shares. TD Cowen reaffirmed a “buy” rating and set a $120.00 price target on shares of TransMedics Group in a report on Wednesday, July 1st. Oppenheimer downgraded shares of TransMedics Group from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 6th. Weiss Ratings cut shares of TransMedics Group from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday, July 28th. UBS Group began coverage on shares of TransMedics Group in a report on Tuesday, July 28th. They issued a “neutral” rating and a $80.00 target price on the stock. Finally, Stifel Nicolaus boosted their price target on shares of TransMedics Group from $75.00 to $80.00 and gave the stock a “hold” rating in a research note on Thursday, June 18th. Six research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, TransMedics Group presently has a consensus rating of “Hold” and a consensus price target of $126.27.

Insider Buying and Selling at TransMedics Group

In other news, Director Thomas J. Gunderson sold 9,624 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $75.06, for a total value of $722,377.44. Following the completion of the transaction, the director owned 16,642 shares in the company, valued at $1,249,148.52. This trade represents a 36.64% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is currently owned by company insiders.

Institutional Trading of TransMedics Group

A number of institutional investors have recently added to or reduced their stakes in TMDX. Harvest Fund Management Co. Ltd purchased a new position in TransMedics Group in the third quarter valued at about $29,000. Allworth Financial LP boosted its stake in shares of TransMedics Group by 74.3% during the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after acquiring an additional 113 shares in the last quarter. Parallel Advisors LLC boosted its stake in shares of TransMedics Group by 42.1% during the 4th quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock worth $34,000 after acquiring an additional 83 shares in the last quarter. US Bancorp DE grew its holdings in shares of TransMedics Group by 24.2% in the 3rd quarter. US Bancorp DE now owns 533 shares of the company’s stock worth $60,000 after acquiring an additional 104 shares during the period. Finally, Atlas Capital Advisors Inc. acquired a new stake in shares of TransMedics Group in the 4th quarter worth approximately $61,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.